Seattle, WA -- (SBWIRE) -- 09/27/2019 -- Rising government support to surge immunization is significantly contributing to growth of the conjugate vaccine market. For instance, rising incidences of zoonotic and infectious diseases in humans lead to increase research & developments for the innovation of new and effective recombinant vaccines for the prevention of diseases. Various governments have taken initiatives to increase awareness regarding vaccination to prevent diseases in the community.
Manufacturing companies have also started some beneficial programs to provide vaccination free of cost to poor people, which is expected to create a highly conducive environment for growth of the global conjugate vaccines market in the near future. For instance, according to the 2014, National Center for Biotechnology Information (NCBI) article, a global introduction of pneumococcal conjugate vaccine (PCV) will help prevent 5.4 – 7.7 million deaths among children by 2030 and will help in achieving goal-4 of the 'Millennium Development Goals'. Considering this, the WHO has recommended the introduction of hemophilic influenzae type b (Hib) and PCV7 in the national immunization schedules of all countries.
Increasing initiatives by various countries to introduce conjugate vaccines in collaboration with funding programs is expected to create a hike in the overall revenue of the global conjugate vaccines market during the forecast period. For instance, in 2015, two countries (Armenia and Azerbaijan) requested to switch from PCV10 to PCV13. Thus, Global Alliance for Vaccines and Immunisation (GAVI) reviewed and approved requests and both countries switched PCV product during 2016.
Request Sample Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2697
The lowest advance market commitment (AMC) price per dose for GAVI eligible countries is currently between US$ 3.30 (PCV13) to US$ 3.05 (PCV10). However, the price per dose for non-Gavi middle-income countries (MICs) that procure PCV through UNICEF can range from US$ 7.00 to US$ 26.87 per dose, depending on manufacturer's differential pricing policies.
Moreover, increasing government funding and support is expected to show lucrative growth for the global conjugate vaccine market. In August 2016, The Sabin Vaccine Institute received an award of US$ 468,328 from the U.S. Centers for Disease Control and Prevention (CDC) to support initiatives to improve sustainable immunization financing. The project, conducted in partnership with the Pan American Health Organization (PAHO), will support sustainable financing, planning, and decision-making for immunization programs in low- and middle-income countries. The program was launched in the Democratic Republic of Congo, Senegal, and Kenya in 2016.
Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.
Request PDF Brochure of This Business Research Report - https://www.coherentmarketinsights.com/insight/request-pdf/2697
Detailed Segmentation:
By Product Type:
Monovalent Conjugate Vaccine
Multivalent Conjugate Vaccine
By Disease Indication:
Pneumococcal
Influenza
Meningococcal
Typhoid
By Pathogen Type:
Bacterial
Viral
By Patients Type:
Pediatric
Adults
Major players operating in the global conjugate vaccine market include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med.
To view the original version on The Express Wire visit https://www.coherentmarketinsights.com/market-insight/conjugate-vaccine-market-2697
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.